Dasatinib
Inquiry
| Post Date: | Jul 04,2015 |
| Expiry Date: | Dec 31,2015 |
| Detailed Description: |
Cas No. :302962-49-8
Dasatinib is approved to treat:
Acute lymphoblastic leukemia that is Philadelphia chromosome positive in patients who are not able to use other drugs. Chronic myelogenous leukemia that is Philadelphia chromosome positive. It may be used in patients who are not able to use other drugs. Dasatinib is also being studied in the treatment of other types of cancer. Dasatinib is a tyrosine kinase inhibitor. It works by blocking proteins that cause the rapid growth of certain types of leukemia cells. This helps the bone marrow to start making normal blood cells again. |
| CAS Registry Number: | 302962-49-8 |
| Synonyms: | ;intermediate;N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide hydrate (1:1);BMS 354825;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide; |
| Molecular Formula: | C22H28ClN7O3S |
| Molecular Weight: | 506.0208 |
| Molecular Structure: | 
|
| Company: | Linyi Lab Pharmaceutical Technology Co., Ltd [ China ] |
| Contact: | luo zhaoliang |
| Tel: | +86-15092968958 |
| Fax: | |
| Email: | pharm_2012@126.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
